Tests WEF-001 in adults with advanced KRAS-mutant solid tumours
Tests WEF-001 alone in adults with advanced KRAS-mutant solid tumours.
Plain-language title generated from the registry record
Registry title: Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 1/2
Where in Canada
- Princess Margareth Cancer CenterToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Auricula Biosciences Inc.
- Trial code
- NCT07148128
- Record updated
- 29 January 2026
- Original description
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.Read full original descriptionShow less
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Inclusion: Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung cancer, platinum-resistant serous ovarian cancer, cholangiocarcinoma or urothelial bladder cancer; Progressive disease following at least one line of standard of care therapy; Measurable disease as defined by RECIST v1.1; ECOG ≤ 1.
Exclusion: Active systemic infection requiring anti-infective therapy within 28 days prior to first dose of IMP; Active cardiovascular disease; Having a second active primary malignancy, requiring systemic administration of any cancer-related therapy; Inflammatory bowel disease; Liver dysfunction; Untreated brain metastasis and/or unstable neurological dysfunction; Active and untreated hyperthyroidism; Lupus erythematosus within past 5 years.